We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

OSU Launches NGS Cancer Panels Using GO Clinical Workbench


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "OSU Launches NGS Cancer Panels Using GO Clinical Workbench"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

GenomOncology has announced that the Ohio State University, College of Medicine, Department Of Pathology will use the company’s GO Clinical Workbench™ to enable clinical reporting of mutations detected from NGS.

“Cancer is a complex disease, with tremendous diversity in pathology and genetics,” commented Weiqiang John Zhao, MD, PhD, FCAP, and Assistant Professor in the Clinical Pathology Branch, The Ohio State University. “The determination of genomic information from an individual’s tumor by NGS can be used to devise treatment approaches that are specific to that patient.”

“NGS generates a significant amount of data and the process of developing clinically useful reports from this data is time consuming. The GO Clinical Workbench has helped us reduce the time to develop a clinically actionable report from half a day to less than an hour,” said Pamela Groen, Laboratory Manager.

GenomOncology’s GO Clinical Workbench streamlines the use of Next Generation Sequencing (NGS) data and allows molecular pathology laboratories to produce an actionable clinical report using the molecular profile of an individual patient’s tumor.

The platform is installed within the institutions firewall and is configured to each laboratory’s specific needs including integration with laboratory systems (LIMS, EMR, etc.), setting of quality control and annotation parameters and custom design of the clinical report.

“Today’s Molecular Pathology lab faces many challenges. Our goal is to enable the lab to produce a comprehensive clinical report that integrates therapy rules, supporting Levels of Evidence, active clinical trials, and complimentary testing modalities to best serve their Oncologists,” added Manuel Glynias, President and CEO of GenomOncology. “Generating this report in a highly efficient, scalable, and compliant manner is our primary focus.”

Advertisement